CAMBRIDGE — Black Diamond Therapeutics, a precision oncology medicine company, has appointed Triangle tech legend and former GSK CEO Robert (Bob) Ingram as its board chairman.

“Black Diamond possesses an innovative and proprietary MAP platform, compelling clinical and early stage assets, and dynamic leadership team, and has the potential to transform the oncology therapeutic landscape,” said Ingram, in a statement.

“I’m thrilled to join as chairman to help Black Diamond achieve its vision of developing precision oncology medicines for all patients with genetically defined cancers.”

Brad Bolzon, chairman and managing director at Versant Ventures and Black Diamond’s founding chairman, will remain on the Company’s board.

Ingram is general partner at Durham-based Hatteras Venture Partners, the region’s leading investor in early stage life sciences companies. He also serves as board chairman of Durham-based BioCryst Pharmaceuticals, and is a board member of Novan, and of HBM Healthcare Investments.

He also serves on the board of the Research Triangle Foundation of North Carolina, the Research Triangle Institute, and is Chairman of the GSK Foundation.

As the ex-CEO and chair of Glaxo-Welcome, meanwhile, he co-led its merger into GlaxoSmithKline.

“Bob is a world-class leader in the pharmaceutical industry,” said David M. Epstein, president and chief executive officer of Black Diamond Therapeutics. “His leadership and expertise will be critical as we continue to execute on our strategy to become a leading precision oncology company.”

Founded in 2017, Black Diamond is a precision oncology medicine company pioneering the discovery of small molecule, tumor-agnostic therapies.

Its proprietary technology platform, Mutation-Allostery-Pharmacology (MAP) platform, is designed to analyze population-level genetic sequencing data to identify oncogenic mutations that promote cancer across tumor types, group these mutations into families, and develop a single small molecule therapy in a tumor-agnostic manner that targets a specific family of mutations.

Bob Ingram, a Triangle tech legend, reflects on region’s growth – and what’s needed now